About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
With the proliferation of e-mail alerts, “chronic fatigue” takes on a whole new meaning.
Nancy L. Greengold, MD, MBA
Dr. Goldenberg discusses ramelteon (Rozerem™) for insomnia, a lidocaine–tetracaine patch (Synera™) for local dermal analgesia, and insulin detemir (Levemir®), a short-acting insulin analogue for type-1 and type-2 diabetes.
Marvin M. Goldenberg, PhD, RPh, MS
Some new therapies include tesaglitazar for insulin-resistant nondiabetic patients; vildagliptin, exenatide, metaglidasen, insulin glargine, pioglitazone, and rimonabant for problems associated with type-2 diabetes; inhaled insulin powder for type-1 diabetes; and pregabalin for reducing pain in diabetic peripheral neuropathy.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Continuing Education Credit
The authors present an overview of some pharmacological and nonpharmacological modalities for treating the widespread public health problem of back pain, a major cause of disability in the U.S.
Roy R. Reeves, DO, PhD, Terrel L. Algood, RPh, and P. Melonee Wise, RPh
David Nash, MD, MBA, describes the concept of benefit-based co-payments, designed so that sick patients would pay less for medications than patients who use medications to prevent illness.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, discusses ways to
reduce the potential for tricks of the mind, including illusions, faulty memory, and unconscious actions, all of which can affect the performance of health care professionals.
Matthew Grissinger, RPh, FASCP
Stephen Barlas explains the recent voluntary guidelines
issued by PhRMA on direct-to-consumer drug advertising.
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Acamprosate Calcium (Campral®): An Effective Treatment for Maintaining Abstinence in Alcohol-Dependent Patients in Combination with Psychosocial Support
Acamprosate calcium (Campral®) may help in
maintaining abstinence from alcohol.
Daniela Espino, PharmD, and Martin P. Cruz, PharmD, CGP